Literature DB >> 16570185

Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET.

Antonia Dimitrakopoulou-Strauss1, Vassilios Georgoulias, Michael Eisenhut, Felix Herth, Sophia Koukouraki, Helmut R Mäcke, Uwe Haberkorn, Ludwig G Strauss.   

Abstract

PURPOSE: Dynamic PET studies with(68)Ga-DOTATOC were performed in patients with non-small cell lung cancer (NSCLC) to assess the somatostatin receptor 2 (SSTR2) expression. Furthermore, dynamic(18)F-fluorodeoxyglucose (FDG) studies were performed in the same patients to compare the SSTR2 expression with the tumour viability.
METHODS: The study population comprised nine patients, examined with both tracers on two different days within 1 week. Standardised uptake values (SUVs) were calculated and a two-tissue compartment model was applied to the data. Furthermore, a non-compartment model based on the fractal dimension (FD) was applied to the data.
RESULTS: The DOTATOC uptake was generally lower than the FDG uptake. Moderately enhanced DOTATOC uptake was noted in seven of the nine tumours. All kinetic parameters except k (4) were lower for DOTATOC than for FDG. The mean SUV was 2.018 for DOTATOC, in comparison to 5.683 for FDG. In particular, k (3) was highly variable for DOTATOC and showed an overlap with the normal lung tissue. The fractional blood volume V (B) was relatively low for both tracers, not exceeding 0.3. The highest significant logarithmic correlation was found for the FD of the two tracers (r=0.764, p=0.017). The logarithmic correlation for SUVs was also significant (r=0.646, p=0.060), as was that forV (B) (r=0.629, p=0.069). In contrast, none of the eight metastases which were positive on FDG PET showed any DOTATOC uptake.
CONCLUSION: The results demonstrated moderate (68)Ga-DOTATOC uptake in primary NSCLC but did not provide any evidence for SSTR2 expression in metastases. This may be caused by loss of the gene expression in metastases as compared with the primary tumours.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16570185     DOI: 10.1007/s00259-005-0063-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  16 in total

1.  A JAVA environment for medical image data analysis: initial application for brain PET quantitation.

Authors:  K Mikolajczyk; M Szabatin; P Rudnicki; M Grodzki; C Burger
Journal:  Med Inform (Lond)       Date:  1998 Jul-Sep

2.  Requirements and implementation of a flexible kinetic modeling tool.

Authors:  C Burger; A Buck
Journal:  J Nucl Med       Date:  1997-11       Impact factor: 10.057

3.  Effective treatment of H838 human non-small cell lung carcinoma with a targeted cytotoxic somatostatin analog, AN-238.

Authors:  Zoltan Szereday; Andrew V Schally; Karoly Szepeshazi; Ana-Maria Bajo; Francine Hebert; Gabor Halmos; Attila Nagy
Journal:  Int J Oncol       Date:  2003-05       Impact factor: 5.650

4.  Somatostatin receptor scintigraphy in the differential diagnosis of meningioma.

Authors:  K H Bohuslavizki; W Brenner; W E Braunsdorf; A Behnke; S Tinnemeyer; H H Hugo; N Jahn; H Wolf; C Sippel; M Clausen; H M Mehdorn; E Henze
Journal:  Nucl Med Commun       Date:  1996-04       Impact factor: 1.690

Review 5.  The applications of PET in clinical oncology.

Authors:  L G Strauss; P S Conti
Journal:  J Nucl Med       Date:  1991-04       Impact factor: 10.057

6.  Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis.

Authors:  A Dimitrakopoulou-Strauss; L G Strauss; C Burger
Journal:  J Nucl Med       Date:  2001-02       Impact factor: 10.057

7.  Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.

Authors:  Marcus Henze; Antonia Dimitrakopoulou-Strauss; Stefanie Milker-Zabel; Jochen Schuhmacher; Ludwig G Strauss; Josef Doll; Helmut R Mäcke; Michael Eisenhut; Jürgen Debus; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

8.  Gene expression of somatostatin receptor subtypes, SSTR1 and SSTR2, in human lung cancer cell lines.

Authors:  T Fujita; Y Yamaji; M Sato; K Murao; J Takahara
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

9.  The utility of 99mTc depreotide compared with F-18 fluorodeoxyglucose positron emission tomography and surgical staging in patients with suspected non-small cell lung cancer.

Authors:  Daniel Kahn; Yusuf Menda; Kemp Kernstine; David Bushnell; Kelley McLaughlin; Sara Miller; Kevin Berbaum
Journal:  Chest       Date:  2004-02       Impact factor: 9.410

10.  99mTc-depreotide scintigraphy of bone lesions in patients with lung cancer.

Authors:  Esther Mena; Valle Camacho; Montserrat Estorch; Jordi Fuertes; Albert Flotats; Ignasi Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-19       Impact factor: 9.236

View more
  32 in total

1.  Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.

Authors:  Sophia Koukouraki; Ludwig G Strauss; Vassilios Georgoulias; Michael Eisenhut; Uwe Haberkorn; Antonia Dimitrakopoulou-Strauss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-06-09       Impact factor: 9.236

2.  Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and Therapeutics.

Authors:  J Clay Callison; Ronald C Walker; Pierre P Massion
Journal:  J Lung Cancer       Date:  2011

3.  Quantitative Analysis of Heterogeneous [18F]FDG Static (SUV) vs. Patlak (Ki) Whole-body PET Imaging Using Different Segmentation Methods: a Simulation Study.

Authors:  Mingzan Zhuang; Nicolas A Karakatsanis; Rudi A J O Dierckx; Habib Zaidi
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

Review 4.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 5.  The Complexity and Fractal Geometry of Nuclear Medicine Images.

Authors:  Fabio Grizzi; Angelo Castello; Dorina Qehajaj; Carlo Russo; Egesta Lopci
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

6.  PET/CT Imaging of NSCLC with a αvβ6 Integrin-Targeting Peptide.

Authors:  Paul Flechsig; Thomas Lindner; Anastasia Loktev; Saskia Roesch; Walter Mier; Max Sauter; Michael Meister; Christel Herold-Mende; Uwe Haberkorn; Annette Altmann
Journal:  Mol Imaging Biol       Date:  2019-10       Impact factor: 3.488

7.  Improved discrimination between benign and malignant LDCT screening-detected lung nodules with dynamic over static 18F-FDG PET as a function of injected dose.

Authors:  Qing Ye; Jing Wu; Yihuan Lu; Mika Naganawa; Jean-Dominique Gallezot; Tianyu Ma; Yaqiang Liu; Lynn Tanoue; Frank Detterbeck; Justin Blasberg; Ming-Kai Chen; Michael Casey; Richard E Carson; Chi Liu
Journal:  Phys Med Biol       Date:  2018-09-06       Impact factor: 3.609

Review 8.  Clinical applications of Gallium-68.

Authors:  Sangeeta Ray Banerjee; Martin G Pomper
Journal:  Appl Radiat Isot       Date:  2013-02-20       Impact factor: 1.513

9.  A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent.

Authors:  Karl Plössl; Rajesh Chandra; Wenchao Qu; Brian P Lieberman; Mei-Ping Kung; Rong Zhou; Bin Huang; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

10.  Volume-normalized uptake rates with robust transportability from PET dual-time and Patlak analyses.

Authors:  Joseph A Thie
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.